Dermata Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
DRMA$0.77+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets: | ||
| Cash and cash equivalents | $7,521,978 | $3,161,570 |
| Prepaid expenses and other current assets | 341,848 | 372,318 |
| Total assets | $7,863,826 | $3,533,888 |
| Liabilities and Stockholders’ Equity: | ||
| Liabilities: | ||
| Accounts payable (including related party amounts of $86,250 and $0, respectively) | $460,811 | $808,011 |
| Accrued and other current liabilities (including related party amounts of $25,000 and $0, respectively) | 1,179,635 | 1,164,783 |
| Total liabilities | 1,640,446 | 1,972,794 |
| Commitments and Contingencies (see Note 7) | - | - |
| Stockholders’ Equity: | ||
| Common Stock, par value $0.0001, 250,000,000 shares authorized as of December 31, 2025, and 2024; 2,660,110 and 251,725 shares issued and outstanding as of December 31, 2025, and 2024, respectively. | 266 | 25 |
| Additional paid-in capital | 79,457,010 | 67,236,408 |
| Accumulated deficit | (73,233,896) | (65,675,339) |
| Total stockholders’ equity | 6,223,380 | 1,561,094 |
| Total liabilities and stockholders’ equity | $7,863,826 | $3,533,888 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.